(NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare ...

MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The ...

said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The company said its EscharEx treatment had previously demonstrated its ability to effectively and ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

The global advanced wound care market is set to witness steady growth, reaching approximately USD 17,302.8 million by 2035 from USD 12,385.4 million in 2025, with a CAGR of 3.4% over the forecast ...

Indications of the disease within individuals usually include mouth sores, skin rashes and lesions, genital sores, leg ulcers and eye ... defense regulator (IDR), a new class of short, synthetic ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.

While eczema is common and not usually life threatening, it can quickly become a severe medical event if the rashes become ...

While eczema is a common condition and typically not life-threatening, it can escalate into a serious medical situation if ...

IRVINE, CA / ACCESS Newswire / February 19, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous ...

IRVINE, CA / ACCESS Newswire / February 28, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, ...